From Injectables to AI: Where Private Equity Is Looking Next

Exectuve Summary

The next important acquisition in aesthetics may not be another product company.

Private equity is moving beyond brands and into the positions that give investors leverage across the market: distribution, education, clinic access, software, data and recurring services.

Our prediction: the next wave of value will come from businesses that sit across the ecosystem, not just inside one product category.

Why we think that

Bridgepoint acquired Vivacy in 2023, giving it a position in injectable aesthetics.[1]

In 2026, it added Obagi Medical, bringing professional skincare into the same portfolio. Bridgepoint itself pointed to potential collaboration between the two businesses.[2]

That is an early sign of the shift.

The strategy is not necessarily to buy more of the same category. It can be to acquire different businesses that reach the same professional customer from different directions.

Crown Laboratories followed a similar logic when it acquired Revance Therapeutics, bringing together skincare, aesthetics and therapeutics.[3]

The pattern then moves further down the value chain.

Growth Partner invested in Healthxchange in September 2026. Healthxchange serves more than 10,000 aesthetic practitioners, and Growth Partner described it as a critical player in the aesthetics value chain.[4]

That gives the investor something very different from a product company: access to thousands of clinic accounts, recurring purchasing, multiple suppliers and an established route to market.

Private capital is also still active at clinic level. Chariot Capital Group acquired Laser Clinics UK in 2026, adding direct exposure to patients, treatment revenue and a physical clinic network.[5]

And education has already become investable.

Rockpool invested in Harley Academy in 2024, backing a business spanning higher education, digital learning and professional training.[6] Outside aesthetics, TPG invested in Healthcademia, an international healthcare education group operating across 11 countries.[7]

Taken together, these are very different assets.

But they all create a strategic position somewhere in the same broader market.

Where the value sits

Products — brands, IP and portfolio breadth

Distribution — access to clinics and recurring purchasing

Clinics — direct patient access and treatment revenue

Education — practitioner attention and professional influence

AI & technology — workflow, data and operational dependency

Wellness — broader access to the same consumer

That is the real shift.

Private equity is not simply asking “what product can we buy?”

It is increasingly asking “where can we sit in the market?”

AI may be the next category

The healthcare investment market already shows how this could evolve.

Ardian acquired a majority stake in Pflegia in July 2026. Pflegia is a digital healthcare recruitment platform using AI-powered matching and process optimisation.[8]

Bain Capital has backed the combination of HealthEdge and UST HealthProof, creating an AI-enabled healthcare technology platform spanning claims, payments, care management and member engagement.[9]

Neither business operates in aesthetics.

But the investment logic is relevant.

A software platform can become embedded inside the day-to-day operation of a healthcare business without manufacturing a physical product at all.

That raises a more interesting question for aesthetics:

Could the next important acquisition be the technology clinics use every day?

CRM, Consultation software,imaging, Patient communication, documentation. inventory, education,AI-supported workflow.

A technology platform can potentially sit across every manufacturer, treatment and product category.

That gives it a different type of strategic value.

Wellness broadens the market again

Optima Health agreed to acquire PAM Healthcare in February 2026 for approximately £100 million, expanding its position in occupational health and wellbeing.[10]

Again, this is not an aesthetics transaction.

But it reinforces the broader direction.

Aesthetics increasingly overlaps with skin health, weight management, diagnostics, preventative health, longevity and wellness.

That creates a wider investment universe around the same consumer.

What could be next?

This is where the existing transactions become useful.

They do not tell us which individual business will be bought next.

But they do point towards the types of assets that may become more attractive.

Distribution — access
Large specialist distributors already sit between manufacturers and thousands of clinics.

Education — influence
Training platforms own professional attention, faculty networks and digital learning infrastructure.

Clinic groups — patients
Multi-site operators provide direct access to treatment revenue and repeat patient relationships.

AI & software — workflow
Platforms that become embedded in how clinics operate can sit across every brand and category.

Professional skincare — recurrence
Repeat purchasing and professional recommendation make the category commercially attractive.

Wellness and longevity — expansion
These businesses extend the relationship beyond traditional aesthetics into a wider consumer-health market.

That is why we think the next phase of investment may look different from the last.

What changes?

For manufacturers, the competitive advantage may increasingly extend beyond the product itself. Distribution, education, first-party clinic access and technology can all strengthen the position around the brand.

For distributors, scale becomes more strategic. A business with thousands of active clinic customers can potentially add products, education, software or services without rebuilding that network from scratch.

For education businesses, the Harley Academy investment already shows that practitioner learning can be treated as a standalone investment platform rather than simply an adjunct to product sales.

For clinics, larger investment-backed platforms could bring stronger infrastructure, technology and services, but also greater consolidation among the businesses supplying and supporting them.

And for technology providers, the opportunity may be particularly significant. A platform embedded in the clinic workflow can operate across manufacturers, products and treatment categories at once.

The bigger picture

Private capital has already moved into products, distribution, clinics and education.

Healthcare investors are also backing AI-enabled infrastructure and broader wellness platforms.

The Harley prediction is that the next important aesthetics deal may come from the infrastructure around the market, rather than the product at the centre of it.

References

[1] Bridgepoint — Vivacy portfolio
https://www.bridgepointgroup.com/investment-strategies/private-equity/portfolio/middle-market/healthcare/vivacy

[2] Bridgepoint — Bridgepoint agrees to acquire Obagi Medical, June 2026
https://www.bridgepointgroup.com/about-us/news-and-insights/press-releases/2026/bridgepoint-agrees-to-acquire-obagi-medical

[3] Crown Laboratories — Completion of acquisition of Revance Therapeutics, February 2025
https://www.crownlaboratories.com/news/crown-laboratories-announces-completion-of-acquisition-of-revance-therapeutics/

[4] Growth Partner — Growth Partner backs Healthxchange, September 2026
https://growthpartner.co.uk/noticeboard/2026/09/01/growth-partner-backs-the-uk-and-irelands-1-aesthetics-distributor/

[5] Eclipse Corporate Finance — June 2026 Healthcare M&A Snapshot, including Laser Clinics UK / Chariot Capital
https://www.eclipsecf.com/post/june-2026-healthcare-m-a-snapshot

[6] Rockpool Investments — Harley Academy portfolio
https://rockpool.uk.com/harley/

[7] TPG — Strategic investment in Healthcademia, November 2025
https://www.tpg.com/news-and-insights/tpg-makes-strategic-investment-in-healthcademia

[8] Ardian — Majority investment in Pflegia, July 2026
https://www.ardian.com/news-insights/press-releases/ardian-acquires-majority-stake-pflegia-germanys-leading-digital

[9] Bain Capital — HealthEdge and UST HealthProof merger, September 2025
https://www.baincapital.com/news/healthedge-and-ust-healthproof-merge-creating-disruptive-ai-powered-healthcare-payer

[10] London Stock Exchange — Optima Health acquisition of PAM Healthcare, February 2026
https://www.londonstockexchange.com/news-article/OPT/acquisition-of-pam-healthcare-limited/17461770